Huda B. Al-Kouatly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huda B. Al-Kouatly has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
Mona M. Makhamreh
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA
13 shared publications- Rodney A. McLaren
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY
8 shared publications - Seth I. Berger
Resarch and Development, Ambry Genetics, Aliso Viejo, CA
8 shared publications - Elizabeth Critchlow
Division of Maternal Fetal Medicine Department of Obstetrics and Gynecology Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA
7 shared publications Stephanie M. Rice
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA
7 shared publicationsRebecca Horgan
6 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
High Diagnosis Rate for Nonimmune Hydrops Fetalis With Prenatal Clinical Genome: Expanded Results From the Hydrops‐Yielding Diagnostic Results of Prenatal Sequencing ( HYDROPS ) Study
Nonimmune hydrops fetalis (NIHF) is characterized by abnormal fluid accumulation in ≥ 2 fetal compartments and may be genetic. The incremental diagnostic yield of prenatal exome sequencing (ES) for NIHF following a negative standard workup was previously explored on 22 cases. We report ES findings in the remaining cohort and investigate the incremental yield of genome sequencing (GS) in cases without a definitive diagnosis from exome. Enrollment criteria and exome methodology for the Hydrops‐Yielding Diagnostic Results of Prenatal Sequencing (HYDROPS) study were previously reported. Exomes without a definitive diagnosis were reviewed with updated clinical information and had GS if DNA was available. A genetic counselor returned the clinical reports. Overall, 50 exomes yielded 22 (44%) diagnoses and six possible diagnoses (12%). Nine new cases (9/28, 68%) had a diagnosis involving one of the following genes: RIT1, SOS1, RYR1, FLT4, LMOD2, KMT2D, PUF60, and BLTP1 . Two additional cases were diagnosed upon reclassification of uncertain variants. GS of eligible ES cases resulted in an incremental diagnostic yield of 7% (1/14). ES and GS in NIHF significantly reduce the number of unexplained cases and guide clinical management and recurrence risks. Currently, the incremental diagnostic yield of GS over ES in NIHF remains under investigation. Trial Registration: ClinicalTrials.gov identifier: NCT03911531
- 20 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
Open AccessHigh Diagnosis Rate for Nonimmune Hydrops Fetalis With Prenatal Clinical Genome: Expanded Results From the Hydrops‐Yielding Diagnostic Results of Prenatal Sequencing ( HYDROPS ) Study
Nonimmune hydrops fetalis (NIHF) is characterized by abnormal fluid accumulation in ≥ 2 fetal compartments and may be genetic. The incremental diagnostic yield of prenatal exome sequencing (ES) for NIHF following a negative standard workup was previously explored on 22 cases. We report ES findings in the remaining cohort and investigate the incremental yield of genome sequencing (GS) in cases without a definitive diagnosis from exome. Enrollment criteria and exome methodology for the Hydrops‐Yielding Diagnostic Results of Prenatal Sequencing (HYDROPS) study were previously reported. Exomes without a definitive diagnosis were reviewed with updated clinical information and had GS if DNA was available. A genetic counselor returned the clinical reports. Overall, 50 exomes yielded 22 (44%) diagnoses and six possible diagnoses (12%). Nine new cases (9/28, 68%) had a diagnosis involving one of the following genes: RIT1, SOS1, RYR1, FLT4, LMOD2, KMT2D, PUF60, and BLTP1 . Two additional cases were diagnosed upon reclassification of uncertain variants. GS of eligible ES cases resulted in an incremental diagnostic yield of 7% (1/14). ES and GS in NIHF significantly reduce the number of unexplained cases and guide clinical management and recurrence risks. Currently, the incremental diagnostic yield of GS over ES in NIHF remains under investigation. Trial Registration: ClinicalTrials.gov identifier: NCT03911531
- Open Access
- 3 February 2026
- Published by Elsevier in Clinical Therapeutics
- Vol. 48 (7) , 592-595
Hereditary Anemias as a Monogenic Etiology for Nonimmune Hydrops Fetalis
- 3 February 2026
- Published by Elsevier in Clinical Therapeutics
- Vol. 48 (7) , 592-595
Open AccessHereditary Anemias as a Monogenic Etiology for Nonimmune Hydrops Fetalis
- Open Access
- 1 February 2026
- Published by Wolters Kluwer Health in O&G Open
- Vol. 3 (1)
Acute Fatty Liver of Pregnancy and Fetal Fatty Acid Oxidation Disorders: A Systematic Review
OBJECTIVE: To evaluate the association between maternal acute fatty liver of pregnancy (AFLP) and fetal fatty acid oxidation (FAO) disorders and to define the clinical and genetic characteristics of mothers with AFLP and their fetuses affected by FAO disorders, we performed a systematic literature review of all reported cases of AFLP that underwent genetic testing for FAO disorders. DATA SOURCES: We searched PubMed, Ovid MEDLINE, Cochrane Library, CINAHL (EBSCO), Scopus, and ClinicalTrials.gov. Terms included were related to AFLP and FAO testing. METHODS OF STUDY SELECTION: We conducted a systematic literature review from inception through May 18, 2025, to evaluate the relationship between AFLP and fetal FAO disorders. Studies were eligible for inclusion if they evaluated the relationship between AFLP and fetal FAO disorders and provided both detailed pregnancy characteristics for AFLP and the workup of maternal and/or fetal FAO disorder. TABULATION, INTEGRATION, AND RESULTS: Twenty-seven studies with 77 AFLP cases that underwent genetic or biochemical testing for maternal or fetal FAO disorders were included. Of these 77 pregnancies, 27 (35.1%) were associated with confirmed fetal FAO disorders. The 27 neonates with FAO disorders included 22 fetuses (81.5%) with LCHAD deficiency, three (11.1%) with medium-chain acyl-CoA dehydrogenase deficiency, one (3.7%) with short-chain acyl-CoA dehydrogenase deficiency, and one (3.7%) with carnitine palmitoyl transferase-I deficiency. Stillbirth and infant mortality was reported in 14 of 22 cases (63.6%) with LCHAD deficiency, and there were no recorded fetal or neonatal deaths with other FAO disorders or those with negative genetic testing. One maternal death was reported in a pregnancy with negative genetic testing for FAO disorders and one patient in a coma at the time of publication with an LCHAD-deficient pregnancy. Presentation of AFLP with gastrointestinal manifestations occurred in 87.8% of patients. CONCLUSION: Acute fatty liver of pregnancy is associated with fetal FAO disorders in about a third of cases, with the most common FAO disorder being LCHAD deficiency. Both AFLP and LCHAD deficiency are associated with high morbidity and mortality in mothers and neonates. Evaluation for fetal and maternal LCHAD deficiency should be part of the diagnostic evaluation in AFLP. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42021247166.
- 1 February 2026
- Published by Wolters Kluwer Health in O&G Open
- Vol. 3 (1)
Open AccessAcute Fatty Liver of Pregnancy and Fetal Fatty Acid Oxidation Disorders: A Systematic Review
OBJECTIVE: To evaluate the association between maternal acute fatty liver of pregnancy (AFLP) and fetal fatty acid oxidation (FAO) disorders and to define the clinical and genetic characteristics of mothers with AFLP and their fetuses affected by FAO disorders, we performed a systematic literature review of all reported cases of AFLP that underwent genetic testing for FAO disorders. DATA SOURCES: We searched PubMed, Ovid MEDLINE, Cochrane Library, CINAHL (EBSCO), Scopus, and ClinicalTrials.gov. Terms included were related to AFLP and FAO testing. METHODS OF STUDY SELECTION: We conducted a systematic literature review from inception through May 18, 2025, to evaluate the relationship between AFLP and fetal FAO disorders. Studies were eligible for inclusion if they evaluated the relationship between AFLP and fetal FAO disorders and provided both detailed pregnancy characteristics for AFLP and the workup of maternal and/or fetal FAO disorder. TABULATION, INTEGRATION, AND RESULTS: Twenty-seven studies with 77 AFLP cases that underwent genetic or biochemical testing for maternal or fetal FAO disorders were included. Of these 77 pregnancies, 27 (35.1%) were associated with confirmed fetal FAO disorders. The 27 neonates with FAO disorders included 22 fetuses (81.5%) with LCHAD deficiency, three (11.1%) with medium-chain acyl-CoA dehydrogenase deficiency, one (3.7%) with short-chain acyl-CoA dehydrogenase deficiency, and one (3.7%) with carnitine palmitoyl transferase-I deficiency. Stillbirth and infant mortality was reported in 14 of 22 cases (63.6%) with LCHAD deficiency, and there were no recorded fetal or neonatal deaths with other FAO disorders or those with negative genetic testing. One maternal death was reported in a pregnancy with negative genetic testing for FAO disorders and one patient in a coma at the time of publication with an LCHAD-deficient pregnancy. Presentation of AFLP with gastrointestinal manifestations occurred in 87.8% of patients. CONCLUSION: Acute fatty liver of pregnancy is associated with fetal FAO disorders in about a third of cases, with the most common FAO disorder being LCHAD deficiency. Both AFLP and LCHAD deficiency are associated with high morbidity and mortality in mothers and neonates. Evaluation for fetal and maternal LCHAD deficiency should be part of the diagnostic evaluation in AFLP. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42021247166.
- Open Access
- 10 July 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-13
Lysosomal storage disorders in nonimmune hydrops fetalis diagnosed by exome sequencing
Lysosomal storage disorders (LSD) are a group of inherited metabolic diseases that contribute to nonimmune hydrops fetalis (NIHF). Our objective was to review the pooled exome sequencing (ES) diagnostic yield of LSD in NIHF cases. We expanded our previous meta-analysis and updated our search strategy of prenatal ES studies from 1/1/2000 to 8/1/2024. Cases with LSD gene variants were reviewed. Variants were curated based on the current American College of Medical Genetics and Genomics and ClinGen guidelines. Forty-one ES studies met our inclusion criteria. A total of 207/558 NIHF cases yielded a positive diagnosis by ES. LSD cases represented 27/558 (5%) of all clinically diagnosed NIHF cases that had ES. Rate of LSD among NIHF cases with positive genetic diagnosis by ES was 27/207 (13%). The 27 diagnostic variants and 4 additional variants of uncertain significance (VUS) were identified in 9 different LSD genes. All variants were inherited with a recurrence risk of 25%. Mucopolysaccharidosis type VII (MPS VII) was most prevalent (14/27, 52%). Also, the 4 cases with VUS were identified in the GUSB gene. Most cases (21/31, 68%) were isolated NIHF. Hydrops recurrence when reported was present in 75% (15/20) of cases. Consanguinity was reported in 57% (12/21) of cases. In conclusion, 5% of all NIHF cases received a genetic diagnosis of LSD by ES. Thirteen percent of NIHF cases that received a genetic diagnosis by ES were attributable to LSD, with MPS VII being the most prevalent condition. Pairing ES results with enzymatic studies can aid variant interpretation and could have potentially upgraded some of the 4 VUS cases, leading to a higher LSD diagnostic yield. Most cases of LSD presenting as NIHF manifest prenatally as isolated NIHF. High rate of NIHF recurrence and consanguinity highlight importance of genetic counseling and testing for LSD.
- 10 July 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-13
Open AccessLysosomal storage disorders in nonimmune hydrops fetalis diagnosed by exome sequencing
Lysosomal storage disorders (LSD) are a group of inherited metabolic diseases that contribute to nonimmune hydrops fetalis (NIHF). Our objective was to review the pooled exome sequencing (ES) diagnostic yield of LSD in NIHF cases. We expanded our previous meta-analysis and updated our search strategy of prenatal ES studies from 1/1/2000 to 8/1/2024. Cases with LSD gene variants were reviewed. Variants were curated based on the current American College of Medical Genetics and Genomics and ClinGen guidelines. Forty-one ES studies met our inclusion criteria. A total of 207/558 NIHF cases yielded a positive diagnosis by ES. LSD cases represented 27/558 (5%) of all clinically diagnosed NIHF cases that had ES. Rate of LSD among NIHF cases with positive genetic diagnosis by ES was 27/207 (13%). The 27 diagnostic variants and 4 additional variants of uncertain significance (VUS) were identified in 9 different LSD genes. All variants were inherited with a recurrence risk of 25%. Mucopolysaccharidosis type VII (MPS VII) was most prevalent (14/27, 52%). Also, the 4 cases with VUS were identified in the GUSB gene. Most cases (21/31, 68%) were isolated NIHF. Hydrops recurrence when reported was present in 75% (15/20) of cases. Consanguinity was reported in 57% (12/21) of cases. In conclusion, 5% of all NIHF cases received a genetic diagnosis of LSD by ES. Thirteen percent of NIHF cases that received a genetic diagnosis by ES were attributable to LSD, with MPS VII being the most prevalent condition. Pairing ES results with enzymatic studies can aid variant interpretation and could have potentially upgraded some of the 4 VUS cases, leading to a higher LSD diagnostic yield. Most cases of LSD presenting as NIHF manifest prenatally as isolated NIHF. High rate of NIHF recurrence and consanguinity highlight importance of genetic counseling and testing for LSD.
- Open Access
- 1 June 2025
- Published by Wolters Kluwer Health in O&G Open
- Vol. 2 (3) , e083
Yield of RASopathy Gene Panel in Karyotype-Normal or Microarray-Normal Fetuses With Increased Nuchal Translucency
OBJECTIVE: To characterize the diagnostic yield of RASopathy gene panels performed due to increased nuchal translucency (NT) measurements with normal karyotype or chromosomal microarray (CMA) results or both. DATA SOURCES: PubMed, OVID, SCOPUS, CINAHL, and ClinicalTrials.gov databases were searched from inception through January 8, 2025 (PROSPERO CRD 42023353582). METHODS OF STUDY SELECTION: Studies were deemed eligible for inclusion if the cohort consisted of fetuses with increased NT with normal karyotype or CMA or both that were tested with a targeted RASopathy gene panel. Quality assessment and critical appraisal of included studies were independently conducted using the Quality Assessment tool for Diagnostic Accuracy Studies. The primary outcome was the diagnostic yield of a RASopathy gene panel in fetuses with increased NT and normal karyotype or CMA or both. Nuchal translucency measurement, associated congenital abnormalities, the presence of cystic hygroma, and the number of genes evaluated in each study were collected. TABULATION, INTEGRATION, AND RESULTS: Our systematic review identified 1,800 cases that met inclusion criteria across 14 studies. The RASopathy gene panel identified a diagnostic variant in 114 cases, for an overall yield of 8.1% (0.081, 95% CI, 0.036–0.139). In fetuses with isolated increased NT, the RASopathy gene panel identified a diagnostic variant in 3.3% of cases (0.033, 95% CI, 0.006–0.074). In fetuses with additional ultrasound abnormalities, the RASopathy gene panel identified a diagnostic variant in 15.1% of cases (0.151, 95% CI, 0.011–0.381). Cardiac abnormalities were the most common associated finding. When a cystic hygroma was identified, total diagnostic yield was 18.4% (0.184, 95% CI, 0.110-0.270). CONCLUSION: Testing for RASopathies with a targeted gene panel identified a diagnostic variant in 3.3% with isolated increased NT and 15.1% with nonisolated increased NT after normal karyotype or CMA or both. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42023353582.
- 1 June 2025
- Published by Wolters Kluwer Health in O&G Open
- Vol. 2 (3) , e083
Open AccessYield of RASopathy Gene Panel in Karyotype-Normal or Microarray-Normal Fetuses With Increased Nuchal Translucency
OBJECTIVE: To characterize the diagnostic yield of RASopathy gene panels performed due to increased nuchal translucency (NT) measurements with normal karyotype or chromosomal microarray (CMA) results or both. DATA SOURCES: PubMed, OVID, SCOPUS, CINAHL, and ClinicalTrials.gov databases were searched from inception through January 8, 2025 (PROSPERO CRD 42023353582). METHODS OF STUDY SELECTION: Studies were deemed eligible for inclusion if the cohort consisted of fetuses with increased NT with normal karyotype or CMA or both that were tested with a targeted RASopathy gene panel. Quality assessment and critical appraisal of included studies were independently conducted using the Quality Assessment tool for Diagnostic Accuracy Studies. The primary outcome was the diagnostic yield of a RASopathy gene panel in fetuses with increased NT and normal karyotype or CMA or both. Nuchal translucency measurement, associated congenital abnormalities, the presence of cystic hygroma, and the number of genes evaluated in each study were collected. TABULATION, INTEGRATION, AND RESULTS: Our systematic review identified 1,800 cases that met inclusion criteria across 14 studies. The RASopathy gene panel identified a diagnostic variant in 114 cases, for an overall yield of 8.1% (0.081, 95% CI, 0.036–0.139). In fetuses with isolated increased NT, the RASopathy gene panel identified a diagnostic variant in 3.3% of cases (0.033, 95% CI, 0.006–0.074). In fetuses with additional ultrasound abnormalities, the RASopathy gene panel identified a diagnostic variant in 15.1% of cases (0.151, 95% CI, 0.011–0.381). Cardiac abnormalities were the most common associated finding. When a cystic hygroma was identified, total diagnostic yield was 18.4% (0.184, 95% CI, 0.110-0.270). CONCLUSION: Testing for RASopathies with a targeted gene panel identified a diagnostic variant in 3.3% with isolated increased NT and 15.1% with nonisolated increased NT after normal karyotype or CMA or both. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42023353582.
- Retracted
- 23 May 2025
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 7 (9) , 101705
Propranolol to decrease time to delivery: a meta-analysis of randomized controlled trials
- 23 May 2025
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 7 (9) , 101705
RetractedPropranolol to decrease time to delivery: a meta-analysis of randomized controlled trials
- 8 February 2025
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 7 (10) , 101634
Trustworthiness Issues in a Meta-Analysis
- 8 February 2025
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 7 (10) , 101634
Trustworthiness Issues in a Meta-Analysis
- Open Access
- 3 September 2024
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (11) , 1381-1397
Prenatal Phenotype of Alkuraya‐Kučinskas Syndrome: A Novel Case and Systematic Literature Review
Alkuraya‐Kučinskas syndrome (AKS) is an autosomal recessive multisystem disorder resulting from mutations in the BLTP1 gene, formerly known as KIAA1109. Primary manifestations include brain malformations, arthrogryposis, and clubfeet. Cardiac, renal, and ophthalmologic abnormalities may also be observed, while nonimmune hydrops is rare. We present a case of two novel BLTP1 canonical splice‐site variants in a fetus with multiple congenital anomalies, including hydrops, a kinked brainstem, and joint contractures. A systematic literature review was conducted to describe the prenatal phenotype of AKS, which was inspired by our case. Our systematic literature review of the prenatal phenotype in 19 cases, including our additional case, demonstrated joint contractures in 90% (18/20), ventriculomegaly in 60% (12/20), brainstem dysgenesis in 50% (10/20), cerebellar hypoplasia in 50% (10/20), parenchymal thinning with lissencephalic aspect in 60% (12/20), and facial dysmorphism in 70% (14/20) of reported AKS cases. In addition to our case, hydrops was reported in two other families. AKS should be considered in fetal presentations with characteristic features, especially brainstem kinking and joint contractures. Exome sequencing, including coverage of canonical intronic splice‐site variants, can clarify the diagnosis.Trial Registration: ClinicalTrials.gov registration: NCT03911531
- 3 September 2024
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (11) , 1381-1397
Open AccessPrenatal Phenotype of Alkuraya‐Kučinskas Syndrome: A Novel Case and Systematic Literature Review
Alkuraya‐Kučinskas syndrome (AKS) is an autosomal recessive multisystem disorder resulting from mutations in the BLTP1 gene, formerly known as KIAA1109. Primary manifestations include brain malformations, arthrogryposis, and clubfeet. Cardiac, renal, and ophthalmologic abnormalities may also be observed, while nonimmune hydrops is rare. We present a case of two novel BLTP1 canonical splice‐site variants in a fetus with multiple congenital anomalies, including hydrops, a kinked brainstem, and joint contractures. A systematic literature review was conducted to describe the prenatal phenotype of AKS, which was inspired by our case. Our systematic literature review of the prenatal phenotype in 19 cases, including our additional case, demonstrated joint contractures in 90% (18/20), ventriculomegaly in 60% (12/20), brainstem dysgenesis in 50% (10/20), cerebellar hypoplasia in 50% (10/20), parenchymal thinning with lissencephalic aspect in 60% (12/20), and facial dysmorphism in 70% (14/20) of reported AKS cases. In addition to our case, hydrops was reported in two other families. AKS should be considered in fetal presentations with characteristic features, especially brainstem kinking and joint contractures. Exome sequencing, including coverage of canonical intronic splice‐site variants, can clarify the diagnosis.Trial Registration: ClinicalTrials.gov registration: NCT03911531
- Retracted
- 7 August 2024
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 6 (10) , 101459
RETRACTED: Propranolol to decrease time to delivery: a meta-analysis of randomized controlled trials
- 7 August 2024
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 6 (10) , 101459
RetractedRETRACTED: Propranolol to decrease time to delivery: a meta-analysis of randomized controlled trials
- Open Access
- 1 August 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 168 (1) , 35-42
Recombinant erythropoietin for the treatment of iron deficiency anemia in pregnancy: A systematic review
Background: Treatment options for severe, refractory iron deficiency anemia are limited in pregnancy.Objective: To review the available literature on the use of recombinant erythropoietin in the treatment of iron deficiency anemia in pregnancy.Search Strategy: An electronic search of seven databases from inception to March 2022 was performed using a combination of keywords.Selection Criteria: We included all randomized controlled or observational studies of pregnant patients with iron deficiency anemia who received recombinant erythropoietin or control. The primary outcome was a change in hematologic parameters (hemoglobin or hematocrit) after treatment. Studies were appraised using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions.Data Collection and Analysis: Data were summarized using narrative synthesis and descriptive statistics as appropriate. This study was registered with PROSPERO, CRD42022313328.Main Results: Of 234 studies screened, five studies met the inclusion criteria and had sufficient data for analysis (n = 103 recombinant erythropoietin and n = 104 controls). All patients in the intervention group received iron supplementation (intravenous or oral) in addition to recombinant erythropoietin. All patients in the control group received iron supplementation (intravenous or oral) alone. As the result of variance between studies in inclusion criteria, the timing of repeat blood draws, and data reporting, a meta‐analysis could not be performed. Three studies found that serial recombinant erythropoietin combined with iron supplementation was more effective at raising hematologic laboratory parameters (hemoglobin or hematocrit) than iron alone. One study reported no difference in hemoglobin or hematocrit levels between groups at day 28. However, patients in this study only received one dose of recombinant erythropoietin, whereas those in the other studies received serial doses. Another study also found no difference in hemoglobin levels by day 28, but patients in the recombinant erythropoietin group had lower hemoglobin levels at baseline and a more rapid rise in hemoglobin than iron alone. This is demonstrated by a more significant rise in hemoglobin at day 11 in the recombinant erythropoietin group than in the control group.Conclusions: Serial recombinant erythropoietin administration and iron supplementation may be more effective at treating refractory iron deficiency anemia in pregnancy than iron supplementation alone.
- 1 August 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 168 (1) , 35-42
Open AccessRecombinant erythropoietin for the treatment of iron deficiency anemia in pregnancy: A systematic review
Background: Treatment options for severe, refractory iron deficiency anemia are limited in pregnancy.Objective: To review the available literature on the use of recombinant erythropoietin in the treatment of iron deficiency anemia in pregnancy.Search Strategy: An electronic search of seven databases from inception to March 2022 was performed using a combination of keywords.Selection Criteria: We included all randomized controlled or observational studies of pregnant patients with iron deficiency anemia who received recombinant erythropoietin or control. The primary outcome was a change in hematologic parameters (hemoglobin or hematocrit) after treatment. Studies were appraised using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions.Data Collection and Analysis: Data were summarized using narrative synthesis and descriptive statistics as appropriate. This study was registered with PROSPERO, CRD42022313328.Main Results: Of 234 studies screened, five studies met the inclusion criteria and had sufficient data for analysis (n = 103 recombinant erythropoietin and n = 104 controls). All patients in the intervention group received iron supplementation (intravenous or oral) in addition to recombinant erythropoietin. All patients in the control group received iron supplementation (intravenous or oral) alone. As the result of variance between studies in inclusion criteria, the timing of repeat blood draws, and data reporting, a meta‐analysis could not be performed. Three studies found that serial recombinant erythropoietin combined with iron supplementation was more effective at raising hematologic laboratory parameters (hemoglobin or hematocrit) than iron alone. One study reported no difference in hemoglobin or hematocrit levels between groups at day 28. However, patients in this study only received one dose of recombinant erythropoietin, whereas those in the other studies received serial doses. Another study also found no difference in hemoglobin levels by day 28, but patients in the recombinant erythropoietin group had lower hemoglobin levels at baseline and a more rapid rise in hemoglobin than iron alone. This is demonstrated by a more significant rise in hemoglobin at day 11 in the recombinant erythropoietin group than in the control group.Conclusions: Serial recombinant erythropoietin administration and iron supplementation may be more effective at treating refractory iron deficiency anemia in pregnancy than iron supplementation alone.